Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF, Schreibelt G, Bloemendal M, van Willigen WW, Hins-de Bree S, de Goede AL, de Boer AJ, Bos KJH, Duiveman-de Boer T, Olde Nordkamp MAM, van Oorschot TGM, Popelier CJ, Pots JM, Scharenborg NM, van de Rakt MWMM, de Ruiter V, van Meeteren WS, van Rossum MM, Croockewit SJ, Koeneman BJ, Creemers JHA, Wortel IMN, Angerer C, Brüning M, Petry K, Dzionek A, van der Veldt AA, van Grünhagen DJ, Werner JEM, Bonenkamp JJ, Haanen JBAG, Boers-Sonderen MJ, Koornstra RHT, Boomsma MF, Aarntzen EHJ, Gotthardt M, Nagarajah J, de Witte TJM, Figdor CG, de Wilt JHW, Textor J, de Groot JWB, Gerritsen WR, de Vries IJM. Bol KF, et al. Among authors: gerritsen wr. Nat Commun. 2024 Feb 23;15(1):1632. doi: 10.1038/s41467-024-45358-0. Nat Commun. 2024. PMID: 38395969 Free PMC article. Clinical Trial.
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ. Boudewijns S, et al. Among authors: gerritsen wr. Oncoimmunology. 2016 May 31;5(7):e1191732. doi: 10.1080/2162402X.2016.1191732. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622047 Free PMC article.
Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.
van Willigen WW, Bloemendal M, Boers-Sonderen MJ, de Groot JWB, Koornstra RHT, van der Veldt AAM, Haanen JBAG, Boudewijns S, Schreibelt G, Gerritsen WR, de Vries IJM, Bol KF. van Willigen WW, et al. Among authors: gerritsen wr. Oncoimmunology. 2020 Mar 22;9(1):1738814. doi: 10.1080/2162402X.2020.1738814. Oncoimmunology. 2020. PMID: 33457087 Free PMC article.
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokx WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, Blank CU, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ. Schreibelt G, et al. Among authors: gerritsen wr. Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28. Clin Cancer Res. 2016. PMID: 26712687 Clinical Trial.
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ. Bol KF, et al. Among authors: gerritsen wr. Oncoimmunology. 2015 Jun 5;5(1):e1057673. doi: 10.1080/2162402X.2015.1057673. eCollection 2016. Oncoimmunology. 2015. PMID: 26942068 Free PMC article.
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Bol KF, et al. Among authors: gerritsen wr. Clin Cancer Res. 2016 Apr 15;22(8):1897-906. doi: 10.1158/1078-0432.CCR-15-1399. Clin Cancer Res. 2016. PMID: 27084743 Review.
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
Boudewijns S, Westdorp H, Koornstra RH, Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de Vries IJ, Gerritsen WR, Bol KF. Boudewijns S, et al. Among authors: gerritsen wr. J Immunother. 2016 Jul-Aug;39(6):241-8. doi: 10.1097/CJI.0000000000000127. J Immunother. 2016. PMID: 27227325 Free PMC article.
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kiliç E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJ. Bol KF, et al. Among authors: gerritsen wr. Ophthalmology. 2016 Oct;123(10):2265-7. doi: 10.1016/j.ophtha.2016.06.027. Epub 2016 Jul 29. Ophthalmology. 2016. PMID: 27476772 Clinical Trial. No abstract available.
213 results